Durviz, intermediary between Mission Bio and the Josep Carreras center
Durviz acts as an intermediary in the current collaboration between Mission Bio and the Josep Carreras Research Center. A job that makes us proud because it is a new acknowledgment of the work that we have been developing for years in the health research sector.
Durviz, intermediary between Mission Bio and the Josep Carreras center
Durviz has been key in the collaboration established by Mission Bio and the Josep Carreras Research Center in Barcelona. A space in which fundamental work will be carried out that will be a boost to our trajectory and a challenge for the future of cancer research
Mission Bio: What is it?
Mission Bio is the name of a US company dedicated to performing high-throughput single-cell DNA and multi-omic analyses. Its main goal is to help researchers and clinicians unlock single-cell biology to enable the discovery, development, and delivery of precision medicine.
It should be noted, at this point, that through its centers of excellence, Mission Bio partners with leaders within the solid tumor and hematologic malignancy research communities. All this with the aim of continuing to build and refine the functionality of Tapestri, the only equipment available on the market capable of simultaneously analyzing DNA and other analytes such as cell surface proteins at the level of a single cell, through its exclusive two-step microfluidic technology.
Its international development and search for alliances has led it to create the first and only Center of Excellence in Europe, located at the Josep Carreras Leukemia Research Institute. A space that will be directed by the renowned doctor Manel Esteller.
Josep Carreras Research Center
The Josep Carreras Research Institute is the first European research center specializing in leukemia and other blood cancers.
Its main research objective is the identification of new therapeutic targets; as well as in the development of more precise and less aggressive treatments by understanding the origin and development of leukemia and other blood cancers.
Manuel Esteller, director of the Josep Carreras Institute, is the author of more than six hundred original publications in peer-reviewed scientific journals. At the same time he is editor-in-chief of “Epigenetics”, and a member of the editorial board of Genome Research. Also, last year, he co-authored a paper in Experimental Hematology. This discussed the benefits of single cell analysis to characterize heterogeneity. Also of the clonal evolution of blood cell subpopulations in myeloid and lymphoid cancers. Some results that can improve the diagnosis of patients, risk stratification and the prescription of targeted therapies.
As Mission Bio’s second single-cell Tapestri Center of Excellence, and the first in Europe, the Josep Carreras Institute will inform academic and industry best practices. It will do this using single cell and multi-omic DNA sequencing in haematological malignancy research. At the same time, it will launch a new program in breast cancer.
The Josep Carreras Institute has long been a benchmark in the development of single-cell analysis and launched a specialized unit in 2021.
The partnership with Mission Bio will boost the Josep Carreras Institute’s application of single-cell DNA sequencing to investigate disease progression. Also its therapeutic resistance and measurable residual disease (MRD) both in blood cancers and in its innovative breast cancer research program.
Durviz as intermediary with Mission Bio
Durviz has been working hand in hand with Mission Bio and the Josep Carreras Foundation for years. And he will be responsible for supplying everything needed to carry out the investigations with Tapestri, Mission Bio’s revolutionary team. A group with which clonal mosaicism and neoplastic transition, clonal evolution, can be questioned. But also metastatic spread with its ability to co-detect SNV and CNV at the single cell level in a scalable manner.
This is very important since it is a tool that allows us to understand resistance to diseases. So users can detect rare emerging clones early. And do it with reliable and sensitive measures of loss of heterozygosity. Which helps them understand how driver mutations are acquired over time that can allow tumor escape and metastasis.
It is also critical for developing single-cell multi-omics analysis. This is of growing importance in oncology precision medicine as it sheds light on the clonal structure of tumors to guide combination therapeutic development and personalized treatment.
A job in which we at Durviz are delighted to participate.
